Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Firebrick Pharma Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution profile is highly concentrated, involving 1 distinct examiner and 1 distinct art unit. This indicates that the company's current patenting efforts are focused on a specific biological or pharmaceutical innovation within a single technical division. The concentration in 1 distinct art unit suggests that the subject matter is specialized and does not span multiple biotechnology disciplines.
ZHANG SPIERING, DONGXIU is the busiest examiner for the portfolio, holding 1 busiest examiner pending action. Because the total pending office actions and the busiest examiner pending count are each 1, this examiner is the only official currently reviewing the company's active applications. The presence of only 1 distinct examiner means that the outcome of the portfolio's current prosecution phase depends on the interactions with this official. Practitioners should analyze the historical allowance rates of ZHANG SPIERING, DONGXIU to better manage the prosecution of this single pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHANG SPIERING, DONGXIU | 1 | 41.2% | +65.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001343 | IMPROVED VIRUCIDAL FORMULATIONS | ZHANG SPIERING, DONGXIU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001343 | IMPROVED VIRUCIDAL FORMULATIONS | ZHANG SPIERING, DONGXIU | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18001343 | IMPROVED VIRUCIDAL FORMULATIONS | ZHANG SPIERING, DONGXIU | 1616 | §103§112 | Final Rejection | — | Pending | Dec 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFirebrick Pharma Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dongxiu Zhang Spiering has the most, with 1 of Firebrick Pharma Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
